drugset / Trial / NCT04432987
Dornase Alpha for the Treatment of COVID-19
Phase 2
Unknown
60 enrolled
Acibadem University
The Scientific and Technological Research Council of Turkey · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
In this study, the effectiveness of the Dornase Alpha treatment, which is known to reduce the viscosity of respiratory secretions, will be investigated in new diagnosed and severe COVID-19 patients separately.
Timeline
- Start
- 2020-05-25
- Primary completion
- 2020-08-25
- Completion
- 2020-09-25
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | dornase alfa | Protein / enzyme biologic | 2.5 mg | — |